According to the report published by Visiongain, the Assisted Reproductive Technology market is estimated to be around USD 23 billion in 2020 and is anticipated to grow at a CAGR of 10% over the forecast period 2020-2030. Assisted Reproductive Technology (ART) is an efficient therapy choice for pairs and people with issues with fertility. A range of main measures are a standard ART process, including pituitary downregulation, regulated ovarian stimulation, ultimate follicular maturation cause, oocyte recovery, fertilization, embryo transfer and luteal support. Individualized therapy protocols may optimize therapy result and decrease safety issues depending on the particular features of each couple. In handling nurses with complicated medical and ethical problems, multidisciplinary team management is crucial.
The 1992 Fertility Clinic Success Rate and Certification Act requires all hospitals offering aided reproductive facilities to disclose outcomes to the Centers for Disease Control and Prevention (CDC) annually.9,10 The Act describes “aided reproductive techniques” as those involving both sperm and egg processing. Most of these require in vivo fertilization (IVF), a method involving the immediate expulsion of oocytes from the flesh of the mother, the combination of sperm and oocytes in the laboratory, and the return of the embryo to the flesh of the woman. Oocyte fertilization happens either by co-incubation of eggs and oocytes (standard IVF) or by direct injection of a separate sperm into the oocyte under microscope visualization (intracytoplasmic embryo introduction or ICSI) ; ICSI is particularly efficient in pairs with issues with egg count and/or operate.
ART, a predominantly unregulated multibillion dollar sector, is the only form of medical therapy where the “end objective is to create another person.”ART contains a broad variety of medical technologies intended to cure infertility or otherwise help impregnate a person who is unable to get impregnated by sexual intercourse. Basic ART involves adjustments in diet, changes in behavior, and drug or hormone therapy. Through these interventions, approximately 85% of infertility instances are settled.
Intrauterine insemination (IUI) and in vivo fertilization (IVF) are more advanced and invasive procedures. IUI is a comparatively easy non-chirurgical operation in which a companion or transplant supplied sperm is carried nearer to the ovum by inserting it into the woman’s uterus during her ovulatory phase. IVF is a more complicated process in which the ova is removed from the woman’s body by laparoscopy, fertilized with semen from her partner or donor, incubated in a laboratory dish until an embryo develops, and then transferred to the woman’s uterus. All but the most basic ART requires treatment by a physician, typically a reproductive endocrinologist or urologist.
Nearly one in six American families will face infertility at some stage, according to projections, and nearly 14 percent of married couples who are not surgically sterile during any specified year are infertile. More exactly, nine out of every 100 women between the sexes of 20 and 44 globally are unable to conceive of a child. As Dave Shade states, “Because disability has only a positive or adverse effect on fertility, individuals with disabilities who want to have kids are similarly or more probable to encounter infertility than the non-infertile population. Thus, at least fourteen quarters of heterosexual adults attempting to conceive, in which at least one spouse has a disability, are anticipated to be infertile in any specified year, and at least one sixth of these people will face infertility sometime during their relationship.”
In 2017, Europe dominated the industry by increasing infertility rates, increasing people’s knowledge of fertility treatment, technological advances and public projects. CDC created a domestic intervention scheme for identification, enhanced efficacy secure therapy, and infertility avoidance in June 2014. The Barcelona Summit suggested setting up an specialist team to resolve demographic problems, expand childcare services and accept clinical trial mother IVF operation.
During the forecast period, technological advances are anticipated to fuel the Australia ART / fertility industry. It was revealed in March 2018 that the Monash IVF will use the intelligent TV tool to advise fertility physicians in China after the clinic signed an arrangement with AC International Medical Tourism (Melbourne) targeting the Chinese industry. Monash IVF, Melbourne’s fertility clinic, has joined into a relationship with the BabySmart tool that allows Chinese nurses to face-to-face meetings with Australia’s clinicians.
Why you should buy Assisted Reproductive Technology Market Forecast 2020-2030: Forecasts and Analysis by Type (IVF, AI-IUI, FER, Others), By End Use (Hospitals, Fertility Clinics), By Diagnosis (Ovulation Testing, Hysterosalpingography, Ovarian Reserve Testing, Genetic Testing, other hormone testing, Imaging tests) and Geography, with Profiles of Leading Companies
What is the future of the Assisted Reproductive Technology market? Visiongain’s comprehensive analysis contains highly quantitative content delivering solid conclusions benefiting your analysis and illustrates new opportunities and potential revenue streams helping you to remain competitive. This definitive report will benefit your decision making and help to direct your future business strategy.
We guarantee in this 171 page report you will receive the following key information –
– View Assisted Reproductive Technology market forecasts and analysis from 2020-2030 to keep you ahead of your competitors and ensure you exploit key business opportunities
– The report provides detailed sales projections of the market, the competitors, and the commercial drivers and restraints allowing you to more effectively compete in the market. In addition to market forecasts from 2020-2030, our new study shows current market data, original critical analysis, and revealing insight into commercial developments
– Assisted Reproductive Technology revenue forecast
– Assisted Reproductive Technology connections forecast
– Examine 122 tables, charts, and graphs.
– Let our analysts present you with a thorough assessment of the current and future Assisted Reproductive Technology market prospects.
– This analysis will achieve quicker, easier understanding. Also you will gain from our analyst’s industry expertise allowing you to demonstrate your authority on the Assisted Reproductive Technology sector
– Discover sales predictions for the key end use submarkets from 2020-2030
– What are the dynamics of the Assisted Reproductive Technology industry? Which submarkets will generate the most revenue? Use our forecasts and expert insight to grow your business and give you more industry influence. Find where you can gain and how your organisation can succeed. Avoid falling behind. Stay informed about the potential for each of these Assisted Reproductive Technology submarkets with individual forecasts and analysis from 2020-2030.
– Type submarket forecast 2020-2030
– Diagnosis submarket forecast 2020-2030
– End-Use submarket forecast 2020-2030
– Learn about the market prospects for the leading Assisted Reproductive Technology market segments 2020-2030
– How will various value chain members perform over the forecast period? Discover where the highest revenue potential lies from 2020-2030, learning about how Assisted Reproductive Technology revenue trickles down through the various market segments. These forecasts will also reveal the competitive landscape. You will see what is happening, explaining the challenges, trends, competitors, and market opportunities. Our report reveals forecasts for the 3 leading segmentations as follows.
– Type Revenue Forecast 2020-2030
– Preimplantation Genetic Diagnosis (PGD) Market Forecast, 2020-2030
– Intracytoplasmic Sperm Injection (ICSI) Market Forecast, 2020-2030
– Gamete Intrafallopian Transfer (GIFT) Market Forecast, 2020-2030
– In-Vitro Fertilization (IVF) Market Forecast, 2020-2030
– Donor Conception Market Forecast, 2020-2030
– Artificial Insemination (AI) Market Forecast, 2020-2030
– Ovulation Induction (OI) Market Forecast, 2020-2030
– Surrogacy Market Forecast, 2020-2030
– Other Type Market Forecast, 2020-2030
– Diagnosis Revenue Forecast 2020-2030
– Hysterosalpingography Market Forecast, 2020-2030
– Ovulation Testing Market Forecast, 2020-2030
– Ovarian Reserve Testing Market Forecast, 2020-2030
– Genetic Testing Market Forecast, 2020-2030
– Other hormone testing Market Forecast, 2020-2030
– Imaging tests Market Forecast, 2020-2030
– End-Use Revenue Forecast 2020-2030
– Hospitals & Clinics Market Forecast, 2020-2030
– Ambulatory Surgical Centers Market Forecast, 2020-2030
– Diagnostic Centers Market Forecast, 2020-2030
– Gynecology Centers Market Forecast, 2020-2030
– Feminist Health Centers Market Forecast, 2020-2030
– IVF Centers Market Forecast, 2020-2030
– Understand the prospects for the 4 regional and the leading 12 national Assisted Reproductive Technology markets – where will the highest revenues and opportunities occur?
– Learn about the market potential for Assisted Reproductive Technology companies in the developed and developing countries, from 2019 onwards. You will see where and how opportunities exist with revealing individual market forecasts and analysis from 2020-2030 for 12 leading national markets by revenue, as well as segmented regional forecasts
– North America Assisted Reproductive Technology revenue forecast 2020-2030
– US Assisted Reproductive Technology revenue forecast 2020-2030
– Canada Assisted Reproductive Technology revenue forecast 2020-2030
– Mexico Assisted Reproductive Technology revenue forecast 2020-2030
– North America Assisted Reproductive Technology by Type revenue forecast 2020-2030
– North America Assisted Reproductive Technology by Diagnosis revenue forecast 2020-2030
– North America Assisted Reproductive Technology by End-Use revenue forecast 2020-2030
– Asia Pacific Assisted Reproductive Technology revenue forecast 2020-2030
– China Assisted Reproductive Technology revenue forecast 2020-2030
– Japan Assisted Reproductive Technology revenue forecast 2020-2030
– India Assisted Reproductive Technology revenue forecast 2020-2030
– Australia Assisted Reproductive Technology revenue forecast 2020-2030
– Rest of Asia Pacific Assisted Reproductive Technology revenue forecast 2020-2030
– Asia Pacific Assisted Reproductive Technology by Type revenue forecast 2020-2030
– Asia Pacific Assisted Reproductive Technology by Diagnosis revenue forecast 2020-2030
– Asia Pacific Assisted Reproductive Technology by End-Use revenue forecast 2020-2030
– European Assisted Reproductive Technology revenue forecast 2020-2030
– Germany Assisted Reproductive Technology revenue forecast 2020-2030
– UK Assisted Reproductive Technology revenue forecast 2020-2030
– France Assisted Reproductive Technology revenue forecast 2020-2030
– Italy Assisted Reproductive Technology revenue forecast 2020-2030
– Spain Assisted Reproductive Technology revenue forecast 2020-2030
– Rest of Europe Assisted Reproductive Technology revenue forecast 2020-2030
– European Assisted Reproductive Technology by Type revenue forecast 2020-2030
– European Assisted Reproductive Technology by Diagnosis revenue forecast 2020-2030
– European Assisted Reproductive Technology by End-Use revenue forecast 2020-2030
– Rest of World Assisted Reproductive Technology revenue forecast 2020-2030
– Rest of World Assisted Reproductive Technology by Type revenue forecast 2020-2030
– Rest of World Assisted Reproductive Technology by Diagnosis revenue forecast 2020-2030
– Rest of World Assisted Reproductive Technology by End-Use revenue forecast 2020-2030
– Explore the factors affecting Assisted Reproductive Technology product developers, and everyone within the value chain. Learn about the forces influencing market dynamics.
– Discover what the present and future outlook for business will be. Learn about the following business critical issues
– Research and development (R&D) strategy
– Technological issues and constraints.
– Competition from new product types
– Increasing specialisation by leading players
– Increasing industry consolidation.
– Advances in product quality
– Analysis of barriers to entry
– Identify who the leading companies are in the Assisted Reproductive Technology industry
– Our report reveals the technologies and companies which hold the greatest potential. In particular, exploring and analyzing the activities of these companies: See where the expected gains will be. View visiongain’s assessment of the prospects for established competitors, rising companies, and new market entrants. Our work explains that potential, helping you stay ahead. Gain a thorough understanding of the competitive landscape with profiles of 10 leading Assisted Reproductive Technology companies examining their positioning, capabilities, product portfolios, R&D activity, services, focus, strategies, M&A activity, and future outlook.
Leading Companies in the Global Assisted Reproductive Technology Market
European Sperm Bank
Parallabs
Ferring Pharmaceuticals
Bloom IVF Centre
Cryolab Ltd.
IrvineScientific
Origio
Microm UK Ltd.
Cosmos Biomedical
Vitrolife
Discover Information found nowhere else in this independent assessment of the Assisted Reproductive Technology market
The Assisted Reproductive Technology Market Forecast 2020-2030: Forecasts and Analysis By Type, By Diagnosis, By End-Use and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Assisted Reproductive Technology sector analysis. With the independent business intelligence found only in our work, you will discover where the prospects are for profit. In particular, our new research provides you with key strategic advantages: Our informed forecasts, independent and objective analysis, exclusive interviews and revealing company profiles will provide you with that necessary edge, allowing you to gain ground over your competitors.
With this report you are less likely to fall behind in knowledge or miss crucial business opportunities. You will save time and receive recognition for your market insight. See how you this report could benefit and enhance your research, analysis, company presentations and ultimately your individual business decisions and your company’s prospects.
What makes this report unique?
Visiongain’s research methodology involves an exclusive blend of primary and secondary sources providing informed analysis. This methodology allows insight into the key drivers and restraints behind market dynamics and competitive developments. The report therefore presents an ideal balance of qualitative analysis combined with extensive quantitative data including global, submarket and regional markets forecasts from 2020-2030
How the Assisted Reproductive Technology Market Forecast 2020-2030: Forecasts and Analysis By Type, By Diagnosis, By End-Use and and Geography, with Profiles of Leading Companies report can benefit you
Visiongain’s report is for anyone requiring analysis of the Assisted Reproductive Technology market. You will discover market forecasts, technological trends, predictions and expert opinion providing you with independent analysis derived from our extensive primary and secondary research. Only by purchasing this report will you receive this critical business intelligence revealing where revenue growth is likely and where the lucrative potential market prospects are. Don’t miss this key opportunity to gain a competitive advantage.
Avoid falling behind your competitors, overlooking critical business opportunities or losing industry influence. In our new report you will discover forecasts from 2020-2030 at the global, submarket, and national level. The report also assesses technologies, competitive forces and expected product pipeline developments. Read on to discover the prospects for the Assisted Reproductive Technology sector and find out what its future market prospects are.
If you buy our report today your knowledge will stay one step ahead of your competitors. Discover how our report could benefit your research, analyses and strategic decisions, saving you time. To gain an understanding of how to tap into the potential of this market and stay one step ahead of the competition you must order now our report the Assisted Reproductive Technology Market Forecast 2020-2030: Forecasts and Analysis By Type, By Diagnosis, By End-Use and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Assisted Reproductive Technology sector analysis. Avoid missing out – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Report Overview
1.1 Global Assisted Reproductive Technology Market Definition
1.2 Global Assisted Reproductive Technology Market Overview
1.3 Global Assisted Reproductive Technology Market Segmentation
1.4 Research Scope of Assisted Reproductive Technology in the Industry
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Methodology
1.8.1 Secondary Research
1.8.2 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Assisted Reproductive Technology Systems Market
2.1 Market Definition
2.2 Industry Structure
2.3 Industry Outlook
2.4 Current Status & Trends
2.4.1 Increasing number of single women and same-sex couples
2.4.2 Constant rise in infertility rate
2.4.3 Growing awareness and social acceptance of assisted reproductive technologies
2.4.4 Changing government regulations
2.5 Product Penetration & growth prospect Analysis
2.5.1 Advanced manufacturing process innovation
3. Global Assisted Reproductive Technology Market Analysis
3.1 PEST Analysis of the Assisted Reproductive Technology Market
3.2 Expert Opinion
3.2.1 Primary Correspondents
3.3 Market Outlook
3.4 Drivers & Restraints
3.5 Dominant Region/Country
3.6 Market Scenario
3.7 Overall Growth Rate, Globally
3.8 SWOT Analysis of the Assisted Reproductive Technology Market
3.8.1 Strengths
3.8.2 Weaknesses
3.8.3 Opportunities
3.8.4 Threats
3.9 Porter’s Five Forces Analysis
3.9.1 Competitive Rivalry
3.9.1.1 Powerful Competitive Strategy
3.9.1.2 Firm Concentration Ratio
3.9.1.3 Degree Of Transparency
3.9.2 Supplier Power
3.9.2.1 Supplier Switching Costs Relative To Firm Switching Costs
3.9.2.2 Supplier Concentration To Firm Concentration Ratio
3.9.2.3 Degree Of Differentiation Of Inputs
3.9.3 Buyer Power
3.9.3.1 Degree Of Dependency Upon Existing Channels Of Distribution
3.9.3.2 Buyer Switching Costs Relative To Firm Switching Costs
3.9.3.3 Buyer Concentration To Firm Concentration Ratio
3.9.4 Threat Of Substitute
3.9.4.1 Buyer Propensity To Substitute
3.9.4.2 Relative Price Performance Of Substitute
3.9.4.3 Perceived Level Of Product Differentiation
3..9.5 Threat Of New Entrant
3.9.5.1 Economies Of Scale
3.9.5.2 Switching Costs Or Sunk Costs
3.9.5.3 Industry Profitability (Market CAGR)
4. Assisted Reproductive Technology: Global Market Analysis by Segments
4.1 Global Assisted Reproductive Technology Market Forecast, by Type 2020-2030
4.1.1 Type Overview
4.1.2 Preimplantation Genetic Diagnosis (PGD) Market Forecast, 2020-2030
4.1.3 Intracytoplasmic Sperm Injection (ICSI) Market Forecast, 2020-2030
4.1.4 Gamete Intrafallopian Transfer (GIFT) Market Forecast, 2020-2030
4.1.5 In-Vitro Fertilization (IVF) Market Forecast, 2020-2030
4.1.6 Donor Conception Market Forecast, 2020-2030
4.1.7 Artificial Insemination (AI) Market Forecast, 2020-2030
4.1.8 Ovulation Induction (OI) Market Forecast, 2020-2030
4.1.9 Surrogacy Market Forecast, 2020-2030
4.1.10 Other Type Market Forecast, 2020-2030
4.2 Global Assisted Reproductive Technology Market Forecast, by Diagnosis 2020-2030
4.2.1 Diagnosis Overview
4.2.2 Hysterosalpingography Market Forecast, 2020-2030
4.2.3 Ovulation Testing Market Forecast, 2020-2030
4.2.4 Ovarian Reserve Testing Market Forecast, 2020-2030
4.2.5 Genetic Testing Market Forecast, 2020-2030
4.2.6 Other hormone testing Market Forecast, 2020-2030
4.2.7 Imaging tests Market Forecast, 2020-2030
4.3 Global Assisted Reproductive Technology Market Forecast, by End-Use 2020-2030
4.3.1 End-Use Overview
4.3.2 Hospitals & Clinics Market Forecast, 2020-2030
4.3.3 Ambulatory Surgical Centers Market Forecast, 2020-2030
4.3.4 Diagnostic Centers Market Forecast, 2020-2030
4.3.5 Gynecology Centers Market Forecast, 2020-2030
4.3.6 Feminist Health Centers Market Forecast, 2020-2030
4.3.7 IVF Centers Market Forecast, 2020-2030
5. Leading Regions in Assisted Reproductive Technology Market 2020-2030
5.1 Regional Overview
5.1.1 North America
5.1.2 Europe
5.1.3 Asia Pacific
5.1.4 LAMEA
5.1.5 Leading Countries/ Regions
5.2 North America Assisted Reproductive Technology Market Forecast, 2020-2030
5.2.1 North America Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030
5.2.2 North America Assisted Reproductive Technology Submarket, By Diagnosis Forecast 2020-2030
5.2.3 North America Assisted Reproductive Technology Submarket, By End-Use Forecast 2020-2030
5.2.4 North America Assisted Reproductive Technology Submarket, By Country Forecast 2020-2030
5.2.4.1 U.S. Assisted Reproductive Technology Market, Forecast 2020-2030
5.2.4.2 Canada Assisted Reproductive Technology Market, Forecast 2020-2030
5.2.4.3 Mexico Assisted Reproductive Technology Market, Forecast 2020-2030
5.3 Europe Assisted Reproductive Technology Market Forecast, 2020-2030
5.3.1 Europe Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030
5.3.2 Europe Assisted Reproductive Technology Submarket, By Diagnosis Forecast 2020-2030
5.3.3 Europe Assisted Reproductive Technology Submarket, By End-Use Forecast 2020-2030
5.3.4 Europe Assisted Reproductive Technology Submarket, By Country Forecast 2020-2030
5.3.4.1 U.K. Assisted Reproductive Technology Market, Forecast 2020-2030
5.3.4.2 Germany Assisted Reproductive Technology Market, Forecast 2020-2030
5.3.4.3 France Assisted Reproductive Technology Market, Forecast 2020-2030
5.3.4.4 Italy Assisted Reproductive Technology Market, Forecast 2020-2030
5.3.4.5 Spain Assisted Reproductive Technology Market, Forecast 2020-2030
5.3.4.6 The Netherlands Assisted Reproductive Technology Market, Forecast 2020-2030
5.3.4.7 Rest of Europe Assisted Reproductive Technology Market, Forecast 2020-2030
5.4 Asia-Pacific Assisted Reproductive Technology Market Forecast, 2020-2030
5.4.1 Asia-Pacific Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030
5.4.2 Asia-Pacific Assisted Reproductive Technology Submarket, By Diagnosis Forecast 2020-2030
5.4.3 Asia-Pacific Assisted Reproductive Technology Submarket, By End-Use Forecast 2020-2030
5.4.4 Asia-Pacific Assisted Reproductive Technology Submarket, By Country Forecast 2020-2030
5.4.4.1 China Assisted Reproductive Technology Market, Forecast 2020-2030
5.4.4.2 India Assisted Reproductive Technology Market, Forecast 2020-2030
5.4.4.3 Japan Assisted Reproductive Technology Market, Forecast 2020-2030
5.4.4.4 Korea Assisted Reproductive Technology Market, Forecast 2020-2030
5.4.4.5 Indonesia Assisted Reproductive Technology Market, Forecast 2020-2030
5.4.4.6 Australia Assisted Reproductive Technology Market, Forecast 2020-2030
5.4.4.7 Rest of Asia-Pacific Assisted Reproductive Technology Market, Forecast 2020-2030
5.5 Rest of World Assisted Reproductive Technology Market Forecast, 2020-2030
5.5.1 Rest of World Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030
5.5.2 Rest of World Assisted Reproductive Technology Submarket, By Diagnosis Forecast 2020-2030
5.5.3 Rest of World Assisted Reproductive Technology Submarket, By End-Use Forecast 2020-2030
6. Leading Companies in The Assisted Reproductive Technology Market
6.1 European Sperm Bank
6.1.1 European Sperm Bank Overview
6.1.2 Analysis of European Sperm Bank Products and Services
6.1.3 European Sperm Bank Primary Market Competitors 2019
6.1.4 European Sperm Bank Key Developments
6.2 Parallabs
6.2.1 Parallabs Company Overview
6.2.2 Analysis of Parallabs Products and Services
6.2.3 Parallabs Primary Market Competitors 2019
6.2.4 Parallabs Key Developments
6.3 Ferring Pharmaceuticals
6.3.1 Ferring Pharmaceuticals Company Overview
6.3.2 Analysis of Ferring Pharmaceuticals Products and Services
6.3.3 Ferring Pharmaceuticals Primary Market Competitors 2019
6.3.4 Ferring Pharmaceuticals Key Developments
6.4 Bloom IVF Centre
6.4.1 Bloom IVF Centre Company Overview
6.4.2 Analysis of Bloom IVF Centre Products and Services
6.4.3 Bloom IVF Centre Primary Market Competitors 2019
6.4.4 Bloom IVF Centre Key Developments
6.5 Cryolab Ltd.
6.5.1 Cryolab Ltd. Company Overview
6.5.2 Analysis of Cryolab Ltd. Products and Services
6.5.3 Cryolab Ltd. Primary Market Competitors 2019
6.5.4 Cryolab Ltd. Key Developments
6.6 IrvineScientific
6.6.1 IrvineScientific Company Overview
6.6.2 Analysis of IrvineScientific Products and Services
6.6.3 IrvineScientific Primary Market Competitors 2019
6.6.4 IrvineScientific Key Developments
6.7 Origio
6.7.1 Origio Company Overview
6.7.2 Analysis of Origio Products and Services
6.7.3 Origio Primary Market Competitors 2019
6.7.4 Origio Key Developments
6.8 Microm UK Ltd.
6.8.1 Microm UK Ltd. Company Overview
6.8.2 Analysis of Microm UK Ltd. Products and Services
6.8.3 Microm UK Ltd. Primary Market Competitors 2019
6.8.4 Microm UK Ltd. Key Developments
6.9 Cosmos Biomedical
6.9.1 Cosmos Biomedical Company Overview
6.9.2 Analysis of Cosmos Biomedical Products and Services
6.9.3 Cosmos Biomedical Primary Market Competitors 2019
6.9.4 Cosmos Biomedical Key Developments
6.10 Vitrolife
6.10.1 Vitrolife Company Overview
6.10.2 Analysis of Vitrolife Products and Services
6.10.3 Vitrolife Primary Market Competitors 2019
6.10.4 Vitrolife Key Developments
7. Conclusions and Recommendations
7.1. Key Research Findings
7.2. Conclusion by Geography
7.3. Conclusion by Solution Type
7.4. Strategic Recommendations
8. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain Report Evaluation Form
List of Figures
Figure 1.1 Global Assisted Reproductive Technology Market Segmentation
Figure 2.1 Assisted Reproductive Technology Value Chain Analysis
Figure 3.1 Assisted Reproductive Technology Supply-Demand Analysis
Figure 4.1 Global Assisted Reproductive Technology Forecast 2020-2030 ($billion, AGR %)
Figure 4.2 Global Assisted Reproductive Technology Market Forecast 2020-2030
Figure 4.3 Global Assisted Reproductive Technology Submarket Forecast by 2020-2030 ($ billion)
Figure 4.4 Global Assisted Reproductive Technology Market By Type Share Forecast 2019, 2025, 2029 (% Share)
Figure 4.19 Global Assisted Reproductive Technology by Submarket By Type Forecast 2020-2030 ($ million)
Figure 4.20 Global Assisted Reproductive Technology Market, by Share Forecast 2019, 2025, 2029 (% Share)
Figure 4.21 Assisted Reproductive Technology Market, By Diagnosis Forecast 2020-2030 ($billion, AGR%)
Figure 4.23 Assisted Reproductive Technology Market, By End-Use System Forecast 2020-2030 ($billion, AGR%)
Figure 4.25 Assisted Reproductive Technology Market, By Type Forecast 2020-2030 ($billion, AGR%)
Figure 4.27 Assisted Reproductive Technology Market, By Diagnosis Forecast 2020-2030 ($billion, AGR%)
Figure 5.1 Regional/Country Assisted Reproductive Technology Market, by 2020-2030
Figure 5.3 Leading Country/Regional Assisted Reproductive Technology Market Share, by 2020
Figure 5.4 Leading Country/Regional Assisted Reproductive Technology Market Share, by 2025
Figure 5.5 Leading Country/Regional Assisted Reproductive Technology Market Share, by 2030
Figure 5.6 Europe Assisted Reproductive Technology Market Forecast 2020-2030 ($billion, AGR%)
Figure 5.7 Europe Assisted Reproductive Technology Market, by Forecast 2020-2030
Figure 5.8 Europe Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030
Figure 5.9 Europe Assisted Reproductive Technology Submarket , By Diagnosis Forecast 2020-2030
Figure 5.10 Europe Assisted Reproductive Technology Submarket , By Country Forecast 2020-2030
Figure 5.11 Europe Assisted Reproductive Technology Submarket , By End-Use 2020-2030 ($billion, AGR%)
Figure 5.10 North America Assisted Reproductive Technology Market Forecast 2020-2030 ($billion, AGR%)
Figure 5.11 North America Assisted Reproductive Technology Market, by Forecast 2020-2030
Figure 5.12 North America Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030
Figure 5.13 North America Assisted Reproductive Technology Submarket , By Diagnosis Forecast 2020-2030
Figure 5.14 North America Assisted Reproductive Technology Submarket , By End-Use Forecast 2020-2030
Figure 5.13 North America Assisted Reproductive Technology Submarket , By Country Forecast 2020-2030
Figure 5.14 Asia-Pacific Assisted Reproductive Technology Market Forecast 2020-2030 ($billion , AGR%)
Figure 5.15 Asia-Pacific Assisted Reproductive Technology Market, by Forecast 2020-2030
Figure 5.16 Asia-Pacific Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030
Figure 5.17 Asia-Pacific Assisted Reproductive Technology Submarket , By Country Forecast 2020-2030
Figure 5.17 Asia-Pacific Assisted Reproductive Technology Submarket , By End-Use Forecast 2020-2030
Figure 5.18 Rest of World Assisted Reproductive Technology Market Forecast 2020-2030 ($billion, AGR%)
Figure 5.19 Rest of World Assisted Reproductive Technology Market, by Forecast 2020-2030
Figure 5.20 Rest of World Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030
Figure 5.21 Rest of World Assisted Reproductive Technology Submarket , By Diagnosis Forecast 2020-2030
Figure 5.21 Rest of World Assisted Reproductive Technology Submarket , By End-Use Forecast 2020-2030
Figure 6.1 3M Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.2 Parallabs Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.3 Ferring Pharmaceuticals Total Company Sales 2013-2019 (US$ Bn, AGR %)
Figure 6.6 Bloom IVF Centre Company Sales 2013-2019 (US$ bn, AGR %)
Figure 6.7 Bloom IVF Centre Revenue % Share, by End-Use Segment, 2019
Figure 6.8 Bloom IVF Centre Revenue % Share, by Geographical Trade, 2019
Figure 6.9 Bloom IVF Centre Revenue % Share, by Business Segment, 2019
Figure 6.10 Cryolab Ltd. Revenue % Share, by Geographic Segment, 2019
Figure 6.11 IrvineScientific Company Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.12 Origio Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.13 Origio Revenue % Share, by Regional Segment, 2019
Figure 6.14 Microm UK Ltd. Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.15 Microm UK Ltd. Revenue % Share, by Regional Segment, 2019
Figure 6.16 Microm UK Ltd. Revenue % Share, by Business Segment, 2019
Figure 6.17 Cosmos Biomedical Total Company Sales 2013-2019 (US$ bn, AGR %)
Figure 6.18 Vitrolife Total Company Revenue 2013-2019 (US$ bn, AGR %)
Figure 6.19 Vitrolife Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.20 Vitrolife Revenue % Share, by Business Segment, 2019
List of Tables
Table 1.0 Research Scope
Table 4.1 Global Assisted Reproductive Technology Market Forecast 2020-2030 ($Bn, AGR %, CAGR %)
Table 4.2 Global Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030 ($billion, AGR %)
Table 4.3 Global Assisted Reproductive Technology Submarket, By End-Use Forecast 2020-2030 ($billion, AGR %)
Table 5.1 Global Assisted Reproductive Technology Market, by Country/Region Forecast 2020-2030 ($billion, AGR %)
Table 5.3 Europe Assisted Reproductive Technology Market Forecast 2020-2030 ($billion, , AGR %, CAGR %)
Table 5.4 Europe Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030 ($billion, AGR %)
Table 5.5 Europe Assisted Reproductive Technology Submarket, By Diagnosis Forecast 2020-2030 ($billion, AGR %)
Table 5.6 North America Assisted Reproductive Technology Market Submarket, By End-Use Forecast 2020-2030 ($billion, , AGR %, CAGR %)
Table 5.7 North America Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030 ($billion, AGR %)
Table 5.8 North America Assisted Reproductive Technology Submarket, By Diagnosis Forecast 2020-2030 ($billion, AGR %)
Table 5.9 Asia-Pacific Assisted Reproductive Technology Market Forecast 2020-2030 ($billion, , AGR %, CAGR %)
Table 5.10 Asia-Pacific Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030 ($billion, AGR %)
Table 5.11 Asia-Pacific Assisted Reproductive Technology Submarket, By Diagnosis Forecast 2020-2030 ($billion, AGR %)
Table 5.12 Rest of World Assisted Reproductive Technology Market Submarket, By End-Use Forecast 2020-2030 ($billion, , AGR %, CAGR %)
Table 5.13 Rest of World Assisted Reproductive Technology Submarket, By Type Forecast 2020-2030 ($billion, AGR %)
Table 5.14 Rest of World Assisted Reproductive Technology Submarket, By Diagnosis Forecast 2020-2030 ($billion, AGR %)
Table 6.1 3M Profile 2019 (Market Entry, Public/Private, Headquarters, Geography, Key Market, Listed on, Products/Services
Table 6.2 3M Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.3 3M Products and Services (Product/Service, Segment)
Table 6.4 3M Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.5 3M Total Company Recent Development 2015-2019
Table 6.6 Parallabs Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.7 Parallabs Products and Services (Product/Service, Segment)
Table 6.8 Parallabs Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.9 Parallabs Total Company Recent Development 2015-2019
Table 6.10 Ferring Pharmaceuticals Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.11 Ferring Pharmaceuticals Products and Services (Product/Service, Segment)
Table 6.12 Ferring Pharmaceuticals Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.13 Ferring Pharmaceuticals Total Company Recent Development 2015-2019
Table 6.14 Bloom IVF Centre Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.15 Bloom IVF Centre Products and Services (Product/Service, Segment)
Table 6.16 Bloom IVF Centre Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.17 Bloom IVF Centre Total Company Recent Development 2015-2019
Table 6.18 Cryolab Ltd. Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.19 Cryolab Ltd. Products and Services (Product/Service, Segment)
Table 6.20 Cryolab Ltd. Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.21 Cryolab Ltd. Total Company Recent Development 2015-2019
Table 6.22 IrvineScientific Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.23 IrvineScientific Products and Services (Product/Service, Segment)
Table 6.24 IrvineScientific Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.25 IrvineScientific Total Company Recent Development 2015-2019
Table 6.26 Origio Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.27 Origio Products and Services (Product/Service, Segment)
Table 6.28 Origio Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.29 Origio Total Company Recent Development 2015-2019
Table 6.30 Microm UK Ltd. Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.31 Microm UK Ltd. Products and Services (Product/Service, Segment)
Table 6.32 Microm UK Ltd. Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.33 Microm UK Ltd. Total Company Recent Development 2015-2019
Table 6.34 Cosmos Biomedical Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.35 Cosmos Biomedical Products and Services (Product/Service, Segment)
Table 6.36 Cosmos Biomedical Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.37 Cosmos Biomedical Total Company Recent Development 2015-2019
Table 6.38 Vitrolife Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.39 Vitrolife Products and Services (Product/Service, Segment)
Table 6.40 Vitrolife Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.41 Vitrolife Total Company Recent Development 2015-2019
European Sperm Bank
Parallabs
Ferring Pharmaceuticals
Bloom IVF Centre
Cryolab Ltd.
IrvineScientific
Origio
Microm UK Ltd.
Cosmos Biomedical
Vitrolife
OvaScience Inc.
Nidacon International AB
Laboratoire CCD
FUJIFILM Irvine Scientific, Inc.
Hamilton Thorne Inc.
CooperSurgical Inc.
Anecova
Merck KGaA
Ovation Fertility
Incept BioSystems
Sylvatica Biotech Inc
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
